NVNO

NVNO

USD

enVVeno Medical Corporation Common Stock

$2.735-0.031 (-1.121%)

Preço em tempo real

Healthcare
Dispositivos médicos
Estados Unidos

Gráfico de preços

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$2.766

Máximo

$2.766

Mínimo

$2.660

Volume

0.00M

Fundamentos da empresa

Capitalização de mercado

48.0M

Setor

Dispositivos médicos

País

United States

Estatísticas de negociação

Volume médio

0.09M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $2.028Atual $2.735Máximo $6.48

Notícias relacionadas

AccessWire

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies hereFRENCHTOWN, NJ / ACCESS Newswire / February 19, 2025 / JTC Team , a fully integrated corporate communications and investor

Ver mais
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand
AccessWire

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life indicators.PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the

Ver mais
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
AccessWire

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.78% of subjects maintained a clinically meaningful

Ver mais
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.